In situ immune response after neoadjuvant chemotherapy for breast cancer predicts survival - PubMed (original) (raw)

Multicenter Study

. 2011 Jul;224(3):389-400.

doi: 10.1002/path.2866. Epub 2011 Mar 25.

Grégoire Mignot, Sandrine Dabakuyo, Laurent Arnould, Lionel Apetoh, Cedric Rébé, Bruno Coudert, Francois Martin, Marie Hélène Bizollon, André Vanoli, Charles Coutant, Pierre Fumoleau, Franck Bonnetain, François Ghiringhelli

Affiliations

Multicenter Study

In situ immune response after neoadjuvant chemotherapy for breast cancer predicts survival

Sylvain Ladoire et al. J Pathol. 2011 Jul.

Abstract

Accumulating preclinical evidence suggests that anticancer immune responses contribute to the success of chemotherapy. However, the predictive value of tumour-infiltrating lymphocytes after neoadjuvant chemotherapy for breast cancer remains unknown. We hypothesized that the nature of the immune infiltrate following neoadjuvant chemotherapy would predict patient survival. In a series of 111 consecutive HER2- and a series of 51 non-HER2-overexpressing breast cancer patients treated by neoadjuvant chemotherapy, we studied by immunohistochemistry tumour infiltration by FOXP3 and CD8 T lymphocytes before and after chemotherapy. Kaplan-Meier analysis and Cox modelling were used to assess relapse-free survival (RFS) and overall survival (OS). A predictive scoring system using American Joint Committee on Cancer (AJCC) pathological staging and immunological markers was created. Association of high CD8 and low FOXP3 cell infiltrates after chemotherapy was significantly associated with improved RFS (p = 0.02) and OS (p = 0.002), and outperformed classical predictive factors in multivariate analysis. A combined score associating CD8/FOXP3 ratio and pathological AJCC staging isolated a subgroup of patients with a long-term overall survival of 100%. Importantly, this score also identified patients with a favourable prognosis in an independent cohort of HER2-negative breast cancer patients. These results suggest that immunological CD8 and FOXP3 cell infiltrate after treatment is an independent predictive factor of survival in breast cancer patients treated with neoadjuvant chemotherapy and provides new insights into the role of the immune milieu and cancer.

Copyright © 2011 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

PubMed Disclaimer

Similar articles

Cited by

Publication types

MeSH terms

Substances

LinkOut - more resources